Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · February 07, 2023

Safety and Efficacy of Bimekizumab Through 2 Years in Patients With Moderate to Severe Plaque Psoriasis

The British Journal of Dermatology

 

Additional Info

The British Journal of Dermatology
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial
Br J Dermatol 2023 Jan 23;188(1)22-31, D Thaçi, R Vender, MA de Rie, C Conrad, DM Pariser, B Strober, V Vanvoorden, M Wang, C Madden, D de Cuyper, AB Kimball

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading